跳至主要内容
临床试验/EUCTR2004-005287-24-AT
EUCTR2004-005287-24-AT进行中(未招募)不适用

Effect of diclofenac-sodium, unpreserved diclofenac-sodium or ketorolac on the inflammatory response after cataract surgery

niv.-Kl. f.Augenheilkunde und Optometrie Wien0 个研究点目标入组 140 人开始时间: 2005年5月24日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male/Female patients suitable for phacoemulsification cataract surgery
  • Aged 40-90 years
  • Able and willing to give Informed Consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • A)Pre-operative: History
  • 1.Presence of pre-proliferative and proliferative diabetic retinopathy with or without diabetic maculopathy
  • 2.Patients with severe systemic dysfunction
  • 3.Ocular surgery or laser therapy, especially if recent, in the operative eye
  • 4.Hypersensitivity to: Diclofenac-sodium, Ketorolac-Trometamol , Prednisolon-21-acetate or any ingredient of the concomitant or study medication
  • 5.Recent treatment with ophthalmic local or systemic anti-inflammatory drugs
  • 6. History of intraocular inflammation / uveitis
  • B)Pre-operative: Examination
  • 1.Ocular malformations like microphthalmia
  • 2.Significant anterior segment ocular disease involving the cornea or uvea
  • 3.Concurrent inflammatory/infective eye disorder e.g. conjunctivitis, episcleritis, blepharitis other than mild seborrhoic blepharitis etc.
  • 4.Severe dry eye syndrome (needing ocular lubricants more than 6 times per day)
  • 5.Cataract secondary to ocular injury/inflammatory eye disease
  • 6.Ocular hypertension or glaucoma under treatment with topical medications other than topical beta-blockers used for at least 28 days prior to study admission
  • 7.Intra-ocular pressure > 26mm Hg with or without treatment
  • 8.Any other disease e.g. pseudo-exfoliation in the operative eye which makes the subject unsuitable for the trial
  • C)Surgery not performed according to the standard operating procedure
  • D)Intra-operative complications and medication:
  • 1.significant corneal, iris or vitreal damage
  • 2.excessive cortical remnants
  • 3.significant anterior chamber bleeding
  • 4.intraocular lens not implanted or significant dislocation of the implant
  • 5.any medication other than those listed in the standard operation procedure for cataract surgery
  • E)Post-operative complications on day 1:
  • 1.wound dehiscence/iris prolapse requiring re-suturing
  • 2.fibrin in the anterior chamber
  • 3.severe intraocular inflammation, infection or bleeding
  • 4.intraocular lens dislocation i.e. optical center of the lens more than 2mm out of the optic axis
  • 5.any other complications e.g. severe conjunctival chemosis on day 1 in the operative eye, considered by the investigator to be adequately significant to interfere with the trial
  • F)Concomitant medication (added post-operative)
  • 1.Any topical ophthalmic medication in the operative eye other than the study medication, artificial tear substitutes and topical antibiotics.
  • 2.Anti-inflammatory systemic medication; however, the use of OTC anti-inflammatory and analgesic drugs such as acetyl salicylic acid and paracetamol for minor conditions
  • (e.g. headache) is acceptable if not more than 2000 mgs per week.
  • 1.Non compliant patients (e.g. not willing to attend the follow up visits)
  • 2.Pregnant or lactating patients or of childbearing potential.
  • 3.Contact lens wearer during the treatment period
  • 4.Known substance abuse (including alcoholism)
  • 5.Participation in another clinical trial
  • 6.Mentally handicapped patients
  • 7.Judged by the investigator to be unsuitable for the study

研究者

发起方
niv.-Kl. f.Augenheilkunde und Optometrie Wien

相似试验